Expertise in Non-Malignant Hematology for Clinical Trials
A Rich History of Expertise
Established in 1973 with the founding of the Platelet and Neutrophil Immunology Laboratory, Versiti Diagnostic Laboratories have a rich history of innovation in diagnostic testing for bleeding, clotting, platelet and neutrophil disorders. Versiti’s hematology laboratories include the Hemostasis Reference Laboratory, Platelet and Neutrophil Immunology Laboratory, and Hematology Genetics Program, which collectively serve nearly 80% of hemophilia treatment centers (HTCs) in the United States. With our deep understanding of the clinical trials landscape, we combine diagnostic testing, assay development, and regulatory support to help bring clinical breakthroughs to patients—ensuring timely and impactful solutions.
A Trusted Laboratory Partner for Rare, Non-Malignant Hematologic Diseases
In partnership with Versiti Blood Research Institute, our labs have led the research and development of numerous groundbreaking diagnostic assays for rare and ultra-rare bleeding and clotting disorders. Versiti’s specialized focus in non-malignant hematology includes research and diagnostic services for diseases including:
Our team of non-malignant hematology experts includes laboratory and medical directors, scientists, researchers, and more, with decades of experience and expertise in these complex disease states.
Meet Our Experts
Ken Friedman, MD
Investigator and Senior Medical Director
Dr. Friedman is an investigaort and senior medical director of hematology at Versiti Comprehensive Center for Bleeding Disorders
Dr. Haberichter is a director of hemostasis and senior investigator whose lab is focused on defining the mechanisms that cause Von Willebrand disease (VWD).
Versiti Blood Research Institute’s Hemostasis, Thrombosis & Vascular Biology program includes basic and clinical research and is home to multiple important breakthroughs in understanding the mechanisms of the regulation of blood clotting. The work of Versiti’s clinical investigators has led to improved outcomes for patients with blood-related diseases, including sickle cell disease, hemophilia and Vvon Willebrand disease.
As part of our ongoing commitment to clinical research, Versiti Blood Research Institute is a proud supporter of the Venous thromboEmbolism Network U.S. (VENUS), the only collaborative clinical trial research network in the U.S. focused on venous thrombosis, including venous thromboembolism (VTE) and pulmonary embolism (PE).
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking ACCEPT, you consent to the use of all the cookies.
